MRA on GMP Inspections between Switzerland and Canada extended
Recommendation
10/11 February 2026
Heidelberg, Germany
Medicinal Products/Drugs meet Medical Devices
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The Mutual Recognition Agreement (MRA on Medicinal Products: Drug GMP Compliance Certification, Sectoral Annex on GMP) between Switzerland and Canada on the GMP certification of medicinal products has been in force since 2000. The text has not been revised since then.
However, Health Canada and Swissmedic have now agreed to extend the existing approach of recognising GMP inspection results to include inspections carried out in countries outside the territories of the respective contracting parties. In addition, "stable" medicinal products derived from human blood or human plasma will be included. In addition, it was agreed to introduce processes for the exchange of information and compliance for product-specific on-site evaluations (OSE) by Health Canada and pre-approval inspections by Swissmedic.
Source: Swissmedic
Related GMP News
03.12.2025What are GMP Audits and what Qualifications do GMP Auditors need to have?
19.11.2025Root Cause Analysis and CAPA - Why FDA Keeps Calling Them Out
22.10.2025EMA Questions & Answers on Mutual Recognition Agreement (MRA) with US updated
22.10.2025FDA continues to take Root Cause Analysis and CAPA very seriously